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bstract
ackground: Secondary tumours (ST) represent a major concern in survivors of Hodgkin’s disease (HD). Breast cancer (BC) is the most
requent ST among young treated women.
aterial and methods: One hundred and eighty-nine women treated for HD by radiotherapy (RT) and/or chemotherapy (CT) subsequently
eveloped 214 BCs.
esults: Median age at HD diagnosis was 25 years (34% were less than 20). Median interval between HD and BC was 18.6 years, with a
2-year median age at first BC. According to the TNM classification, there were 30 (14%) T0 (non palbable lesions), 86 (40%) T1, 56 (26%)
2, 13 (6%) T3T4 and 29 (14%) Tx. There were 25 (13.2%) contralateral BC. 160 (75%) and 15 (7%) tumours were infiltrating ductal and
obular carcinomas, 7 (3.3%) were other subtypes and 27 (22%) DCIS.
The rate of axillary nodal involvement was 32%. Among 203 operated tumours, 79 (39%) were treated by breast conserving surgery
BCS), with RT in 56 (71%) cases. CT and hormonal treatment were delivered in 51% and 45% of the patients. With a 50-month median
ollow-up, local recurrence occurred in 12% of the tumours (9% after mastectomy, 21% after lumpectomy alone and 13.7% after lumpec-
omy with RT). Metastasis occurred in 47 (26%) patients. The risk factors were pN+, pT, high SBR grade and young age (<50 years).
he ten-year overall and specific survival rates were 53% and 63.5%, respectively. The ten-year specific survival rates were 79% for
T0T1T2, 48% for pT3T4 (p = 0.0002) and 79% for pN0 versus 38.5% for pN+ (p = 0.00026). Among 67 deaths, 43 (73%) were due to
C.
onclusion: Patients and physicians should be aware that BC is the most frequent secondary tumour in young women treated for HD. The
ew RT modalities (lower doses and involved fields) may decrease the risk in the future. However, these women require a careful monitoring
s from 8 to 10 years after HD treatment, combining mammography, ultrasound and MRI according to several ongoing studies. BC with
hole breast irradiation is feasible in some selected cases.
2011 Published by Elsevier Ireland Ltd.
eywords: Breast cancer; Hodgkin’s disease; Secondary cancers; Radio-induced cancers; Breast conserving treatment; Thoracic irradiation; Ductal carcinoma
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. Introduction
Until the 50s, Hodgkin’s disease (HD) was a permanent
atal disease. In the 60s, radiotherapy (RT) and chemotherapy
CT) radically changed prognosis, especially using large field
rradiations and polychemotherapies. However, after such
reatments, several long-term side-effects were observed and
he occurrence of second primary cancers still remains the
ost important [1–4].
Many reports have confirmed a significant increased risk
f secondary acute non-lymphocytic leukaemia (ANLL),
on-Hodgkin’s lymphoma (NHL) and solid tumours (ST)
mong HD long-term survivors [5–7].
Breast cancer (BC) is the most frequent ST occurring
n women treated for HD [8–17]. The “latency interval” is
uite long, i.e. approximately 15 years, and the risk dramat-
cally increases in young girls and adolescents until 20–25
ears old. Several reports have brought data on BC incidence
mong large cohorts of women treated for HD, but relatively
ew data are available on the clinico-pathological character-
stics, treatment modalities (especially possible treatment by
reast conserving therapy including whole breast irradiation)
nd more particularly outcome in patients with secondary
C.
Thus, after a previous study published in 2001 [18],
e performed a new retrospective and multicentric review
o assess the specific histopathological features, locore-
ional and systemic treatments as well as prognostic
actors of such secondary BC. Finally, we tried to suggest
reventive actions by specific screening and/or chemopre-
ention. 7. Material and methods
In a retrospective international study performed in 14 hos-
itals, private clinics and cancer centres, 189 women treated
or HD who subsequently developed a total of 214 BCs were
ound. The clinical and histological data for BC were almost
ully obtained. However, several parameters for HD were not
xhaustive (stage/treatment details), especially in older cases
45% of the cases with an over 20-year interval between HD
nd BC) and for some of the patients treated for HD else-
here and further referred to one of the 14 centres only after
C diagnosis. To our knowledge, this study describes the
argest series on detailed clinical and histological features of
C occurring after HD treatment.
.1. Statistics
The analysis was performed using the Kaplan–Meier
ethod for disease-specific survival. Deaths of patients with
o evidence of BC and from causes not related to BC were
ensored in the product-limit calculation of specific survival.
he Mantel–Cox (log-rank) test was used to compare survival
urves.
. Results
.1. HD clinico-pathological features and treatmentsThe median age at diagnosis of HD was 25 years (range
–67 years). Globally, 47 women (34.4%) were 20 years old
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Table 1
Clinico-pathological features for Hodgkin’s disease (HD). Analysis of 189
patients.
%
Treatment period
<1970 17
1970–1980 38
1981–1990 34
>1990 11
Age at diagnosis
<20 years 25
20–30 years 45
>30 years 30
Ann Arbor stage (n = 169)
I 22
II 56
III 16
IV 6
Histology (n = 133)
Lymphocyte predominance 9
Nodular sclerosis 63
Mixed cellularity 23
Lymphocyte depletion 5
Treatment (n = 185)
RT alone 28
CT alone 2.7
RT + CT 69.3
RT technique (n = 182)
Mantle 79
Involved fields 21
Supradiaphragmatic RT doses (Gy)
<36 7
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339–40 66
>40 27
r less and three were young girls (7, 8 and 9 years old). Main
linico-pathological features of HD were detailed in Table 1.
ne hundred and eighty-two patients underwent radiother-
py (RT): alone in 28% of the cases and associated with
hemotherapy (CT) in 69%. All patients received supradi-
phragmatic RT, mainly by classical mantle (extended) field.
he X-ray energies used were: cobalt photons: 79, 6–10 X
egavolts: 27, 15–25 megavolts: 35 and not specified: 41.
ifty-eight patients (34%) underwent splenectomy and 54
ubdiaphragmatic irradiation. Only 5 women (2.6%) were
reated exclusively by CT, whereas 128 (69%) underwent CT
nd RT. MOPP protocol was used in 57 patients, ABVD in
7 and a MOPP-ABVD combination in 25; 29 patients were
reated by other combinations, mainly based on vinblastine.
he median number of delivered cycles was 6. Twenty-one
11%) women relapsed after various time intervals; three
ere treated by RT alone, 10 by CT alone and 8 by both
odalities.
.2. Breast cancer: clinical characteristics
The median interval after HD treatment and BC occur-
ence was 18.6 years (range 2–50 years), with no significant
ifferences according to initial HD treatment: RT alone: 17
ears, CT + RT: 19 years. BC occurred after HD diagnosis
3
oogy/Hematology 81 (2012) 29–37 31
ithin 10 years, between 10 and 20 years and after 20 years
n 9.6%, 45.4% and 45% of the cases, respectively. Median
ge at diagnosis of the first BC was 42 years.
According to TNM classification, we found (all cases
ncluded) 30 (14%) T0 (non palpable lesions), 86 (40.1%)
1, 56 (26.2%) T2, 13 (6%) T3T4 and 29 (13.6%) Tx. There
ere 25 contralateral BC (13.2%), of which 3 synchronous
nd 22 metachronous.
Thirty-six (19%) tumours were multifocal. Six (3.2%)
atients had metastases at first diagnosis.
.3. Breast cancer: histopathological features
160 (74.7%) tumours were infiltrating ductal carcinomas
IDC), 15 (7%) were infiltrating lobular carcinomas (ILC),
(3.3%) were other infiltrating subtypes and 27 (21.6%)
ere ductal carcinomas in situ (DCIS). Five cases were not
pecified.
Among 164 out of 187 evaluable infiltrating carcinomas,
0 (18%) were SBR I (Scarff-Bloom-Richardson histoprog-
ostic grade), 70 (43%) were SBR II and 64 (39%) were SBR
II.
Among 149 evaluable tumours, estrogen (ER) and pro-
estin (PgR) receptors were positive in 58.4% and 51.4% of
he cases, respectively (with a global ER and/or PgR posi-
ivity rate of 65%). Her2 overexpression was found in 5 out
f 41 (21%) IBC treated after 2001. Among 168 infiltrating
arcinomas for which axillary dissection was performed, 115
68%) had no axillary involvement (pN0), 37 (22%) had 1– 3
nvolved nodes (pN1) and 13 (8%) had more than 3 involved
odes (pN2–3). In three cases (2%), the number of involved
odes was not specified.
.4. Breast cancer: treatment
Four metastatic patients and another two with advanced
esions (T4N1) only received medical treatment. Among 203
perated tumours, 79 (39%) were treated by lumpectomy
r quadrantectomy (8/27 (29.6%) DCIS and 71/176 (40.3%)
nfiltrating carcinomas) and 124 (61%) by mastectomy. Axil-
ary dissection was performed in 168 out of 187 cases.
After conservative surgery, whole breast irradiation was
elivered in 56 out of 79 (71%) cases: 5/8 (62%) in DCIS
nd 51/71 (72%) in infiltrating carcinomas.
After mastectomy, radiotherapy was delivered only in 11
ut of 121 (9%) cases. Chemotherapy (CT) was delivered
n 95 out of 187 (51%) patients with infiltrating carcinoma
associated with Trastuzumab in five cases). Hormonal treat-
ent (HT) was used in 93 cases (45%). CT and HT were both
trongly influenced by axillary nodal status and age (Table 2).
.5. Outcome.5.1. Locoregional recurrences
With a 50-month median follow-up, twenty-five (12%) out
f 210 evaluable tumours underwent local recurrence: 3 out
32 B. Cutuli et al. / Critical Reviews in Oncology/Hematology 81 (2012) 29–37
Table 2
Influence of axillary nodal status and age on chemotherapy (CT) and hormonal treatment (HT) use.
CT use (%) p HT use (%) p
Axillary nodal status
pN0 37
<0.0001
45
0.26pN1–3 81 46
pN>3 84.6 69
Age
≤50 years 59.5
0.0041
37
0.0005654
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Table 3
Metastatic risk factors (univariate analysis).
Metastases
n % p
pT
pT0 − pT1 17/97 17.5
pT2 27/5 51.9 <0.0001
pT3 − pT4 2/6 33.3
pN
pN0 19/99 19.2
pN1–3 13/34 38.2 <0.0001
pN>3 11/12 91.7
SBR
I 0/23
II 21/62 33.9 0.0022
III 21/54 38.9
Age
<50 years 39/105 37
≤50 years 8/51 15.7 0.0061
Delay HD-BC
<10 years 5/14 35.7
10–20 20/75 26.7 NS
>20 years 22/67 32.8>50 years 37.7
f 26 (11.5%) among DCIS and 22 out of 184 (12%) among
nvasive tumours.
Among invasive tumours treated by conservative surgery
lone, 4 out of 19 (21%) relapsed, compared to 7 out of 51
13.7%) when radiotherapy was added.
Nine out of 100 (9%) patients treated by mastectomy
elapsed. On the other hand, one out of three DCIS treated by
onservative surgery alone relapsed, whereas there were no
R among four DCIS treated with RT. There were two LR
mong 18 DCIS treated by mastectomy.
Six nodal recurrences were reported: two in the axilla, two
n the supra-clavicular fossa, one in the internal mammary
hain and one without specified topography.
.5.2. Metastases
Six patients were metastatic at time of diagnosis. Among
83 patients with initial localized disease, 47 (27%) further
eveloped metastasis. The metastatic risk was much higher in
omen with BC diagnosis under 50 than in older ones (37%
ersus 15.7%, p = 0.0061), and was significantly influenced
y pT status (17.5% for pT0–T1 versus 50% for pT2T3T4,
< 0.0001), pN status (19.2% for pN versus 52.2% for0
N+) (p = 0.0001) and SBR grading (II–III versus I, 36.2%,
= 0.0022), whereas hormone receptor status and HD-BC
elay did not (Table 3).
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Fig. 1. Overall (OS) and disease specific survival (DSS) rates.
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Fig. 2. Disease specific survival (DSS) rates according to pT.
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.5.3. Overall and disease-specific survival rates
The overall 5- and 10-year survival rates were 69.8% and
2.7%. The corresponding breast cancer specific rates were
2% and 63.5% (Fig. 1).
The 5- and 10-year breast cancer specific survival rates
ere 84% and 78.6% for pT0T1T2 versus 60.6% and 48.2%
or pT3T4 (p = 0.0002) (Fig. 2).
The 5- and 10-year breast cancer specific survival rates
ere 81% and 79% for pN0 versus 68.2% and 38.5% for
N+ (p = 0.00026) (Fig. 3).
The 5- and 10-year breast cancer survival rates were 75.8%
nd 70.7% for conservative surgery versus 76.6% and 63.7%
or mastectomy, respectively (Fig. 4).
Twenty-three patients developed secondary cancer of var-
ous types, including four lung cancers, three skin, three
hyroid and three cervix cancers.
Lately, 67 patients (35%) died and 122 were still alive.
he 67 deaths were due to: breast cancer: 43 (73%), other
l
t
pSS) rates according to pN.
econd cancer: 7 (12%), HD or BC treatment complications:
(6.8%), and intercurrent disease: 5 (8.5%). In eight cases
13%), the cause was unknown.
. Discussion
The outstanding improvement in Hodgkin’s disease
urvival rates was unfortunately associated to long-term
ccurrence of various types of secondary tumours [1–6].
cute leukaemia (especially ANLL) was the first malignancy
hown to be induced by HD therapy, generally related to drug
ombination containing alkylating agents [19].
NHL also occurred at various intervals, especially after
ombination of CT and RT for HD.ST incidence is more delayed with often a 10–20-year
atency period, and continues to increase with time observa-
ion. ST were observed after RT alone, CT alone and more
articularly with CT + RT association.
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Secondary cancers represent the most important compli-
ation of HD treatments, not only in terms of morbidity, but
lso mortality [20]. A 10–20% 15-year cumulative incidence
f ANLL, NHL and ST was reported in the majority of the
eries and even more with a longer follow-up. However, it
s important to underline several discrepancies among these
tudies, with median ages at HD diagnosis varying from 11
o 43 years, wide variations in proportions among three clas-
ical HD treatments (RT/RT + CT/CT) as well as rates of HD
elapses and “salvage treatments”. Moreover, the follow-up
ange varied from 6 to 15 years. In a large German study,
mong 127 secondary ST occurred with a 72-month follow-
p, the most frequent tumours were lung (24%), colorectal
20%) and breast (10%) [21]. Similar results were found in the
argest study on 32,591 HD treated from 1935 to 1994 [1]. In a
utch study, the RR of ST increased greatly with younger age
t first HD treatment with RRs of 4.9, 6.9 and 12.7 for patients
rst treated at 31 to 39, 21 to 30 and under 20 years old,
espectively [7]. Another very large British study including
519 patients treated for HD confirmed that age at treat-
ent has a major effect on risk of second malignancies [8].
mong women, breast cancer represents the most frequent
T [8–17]. After several “sporadic” reports in the 80s, many
arge international (often multicentric) studies confirmed a
ong-term high risk of BC development in children, teenagers
nd young women (under 25) treated for HD, especially by
ide radiotherapy fields (i.e. mantle). Young age, especially
peri-pubertal” period, seems to be the most important risk
actor for BC occurrence, corresponding to the highest breast
adiosensitivity period.
In a Scandinavian multicentric report [6], among 670 girls
reated for HD at 16-year median age (treatment modalities
ot specified), the cumulative risks of BC were 5% and 12%
fter 20 and 30 years of follow-up, respectively. In another
tudy from Stanford [22], among 307 girls also treated for HD
RT alone: 46%, RT + CT: 51% and CT alone: 3%) at 16-year
edian age, the 20-year actuarial risk of BC was 9.2%. In a
aediatric multicentric study [23], among 483 girls treated for
y
d
s) rates according to surgery.
D at 11-year median age (RT alone: 23%, RT + CT: 69% and
T alone: 3%), 30 developed 42 BC at 32-year median age.
welve out of 30 (40%) had bilateral disease. The estimated
ctuarial cumulative probability of BC was 17% (95% CI:
.4–24.5) at 30 years of age. In an international multicentric
tudy [24] conducted among 5925 young patients (<21 years)
reated for HD, and including 2725 females, 52 BC were
bserved. In comparison with general population, the RRs
ere 22.9 and 11.6 among those treated from 10 to 16 and
7 to 20 years old, respectively.
A debate on the real influence of high or low RT doses,
s well as large or “involved” fields used for HD cure, is
till ongoing [25,26]. However, a retrospective analysis of
he doses delivered to different parts of the breasts is almost
mpossible and the doses are often wrongly estimated due to
ifficulties of precise measurement [18,27]. Many parame-
ers are variable, e.g. morphology of the patients (influenced
y age treatment, height and weight, and size and shape of the
reast), and irradiation modalities. The disease extent, espe-
ially the importance of mediastinal involvement, influences
he field size, and consequently delivered doses to inner breast
uadrants. Furthermore, especially in patients treated before
he 1980s, important variations in energy used (i.e. orthovolt-
ge, cobalt photons) and fraction doses (from 1.8 to 2.5 Gy),
s well as the number of daily treated fields were observed.
n two experimental dosimetric studies using a thermolumi-
escent dosimeter in a phantom, the measurements showed
hat a wide range of doses (0.6–27.4 Gy) were delivered to
he breast from mantle field irradiation [27,28]. In an interna-
ional case-control study [29], there were slight different BC
elative risk for women treated by mediastinal RT at 20–40
y versus more than 40 Gy: 8.5 (95% CI: 5.4–13.2) versus
0.5 (95% CI: 6.8–16). With addition of alkylating-based
T, the risk was halved in both groups. Another Dutch case-
ontrol study including 770 women treated for HD under 41
ears showed similar results [30]. In a meta-analysis of ran-
omised trials [2], there was a significantly greater risk of
econdary BC with extended-field RT (OR = 3.25, p = 0.04),
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Table 4
Comparison between series describing BC after HD in detail.
Authors N HD age HD treatment (%) HD-BC delay BC age BC histology (%) Death by BC (%)
RT RT + CT IC DCIS pN + %
Yahalom [33] 37 (45)a 27 73 27 15 43 82 18 31 22
Aisenberg [10] 14 (16)a 24 71 29 16 40 94 6 17 7b
Gervais-Fagnou [52] 15 (17)a 25 73 27 17 41 93 7 25 13
Wolden [22] 65 (71)a 25 58 42 18 43 87 13 27 23
Cutuli [18] 119 (133)a 24 62 38 15 41 90 10 54 30
El-Din [34] 28 (39)a 25 50 50 16 45 85 15 32 NS
Meattini [53] 39 31 54 37c 19.5 51 86 14 21 31
Present series 189 (214)a 25 28 72 18.5 42 87 13 32 23
IC, infiltrating carcinoma; DCIS, ductal carcinoma in situ.
a Bilateral BC (synchronous + metachronous).
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c 8% treated by CT alone.
ut not for all other secondary tumours. On the other hand,
wo studies [26,30] showed a wide increased BC risk in case
f exclusive mantle radiotherapy, but with a reduced risk by
rradiation of mediastinum only or associated subdiaphrag-
atic RT, as well as CT use. Indeed, mediastinal RT alone
without axillary field such as in classical ‘mantle” field)
pares approximately 50% of the breast tissues [31] (espe-
ially upper external quadrants, the most common size of BC
nset). On the other hand, both CT (especially with alkylating
gents) and supradiaphragmatic RT induce a high rate of per-
anent menopause, which is a well-known protective factor
gainst BC, whereas the role of splenectomy or subsequent
C risk is discussed. In one report [32], splenectomy was
he only variable associated with increased risk of BC, but
he number of compared patients was small, with different
haracteristics, especially regarding age, treatment modal-
ties and survival. Other studies did not find splenectomy
s a risk factor. Those secondary BC were almost always
reated by mastectomy [22,28,33,34], thinking that a con-
ervative treatment with breast irradiation was not feasible.
owever, in our previous report [18], 32 out of 121 (26%)
atients underwent breast conservative surgery with whole
reast irradiation. The local recurrence (LR) rate was 12.5%
ersus 29% among 12 patients without RT after conservative
urgery. No unfavourable side-effects of this treatment were
bserved, such as in another four reports [32,33,35,36]. In the
atest report from Canada, all five patients tolerated breast RT
ery well, and toxicity was limited to grade-1 events [36].
he present study confirms these findings, with 56 (27%)
atients who underwent whole breast irradiation after conser-
ative surgery. The LR rate was 13.7%, according to the rates
bserved in young patients (<40 or <50 years) in sporadic
ases in the literature [37,38].
No fibrosis or necrosis was reported. Indeed, especially
fter HD treatment by high dose photons (6–18 MV), and in
ontrast with old orthovoltage and cobalt treatments which
idely increased skin and subcutaneous doses, the use oflassical tangential fields (thus with different angles com-
ared to classical antero-posterior supradiaphragmatic fields)
s feasible after previous dosimetric evaluation. In our expe-
d
f
tience, many patients were treated by 1.8 Gy per fraction
n order to minimize the long-term risk of fibrosis. Other
eams reported some cases treated by various partial breast
rradiation techniques, as well as brachytherapy or intraoper-
tive radiotherapy with electrons [39,40]. The possibility of
new breast treatment by photons, electrons or brachyther-
py was already confirmed by other studies in selected cases
small and late local recurrences) after a first radiosurgical
reast conserving treatment [41,42]. On the other hand, due
o a better awareness of BC risk after HD treatment both in
atients and physicians, mammographic screening increased
n this high-risk population. Indeed, the T0T1 rate was 54%
116/214) in the present study versus 44% (59/133) in the
001 report. The T2 rates were similar (26% and 27%), but
very important decrease in the T3T4 group was observed
from 18% to 6%). This global “shifting” stage explains the
xillary nodal involvement fall from 54% in our previous
eport to 32% in our current study. Similarly, the metastasis
ates decreased from 33% to 27%. Very similar data were
bserved in a large survey in France after full development
f the national screening program [43]. Thus, an early diag-
osis of these secondary BC is extremely important. Due to
atency between HD treatment and BC occurrence, the mam-
ographic screening should be started 10 years later in young
omen treated before 25 years [44]. Several authors recom-
end to add ultrasound and/or magnetic resonance imaging
MRI) to improve the screening efficiency, such as in high-
isk women with BRCA 1-BRCA 2 mutations [45,46]. In a
ide English screening programme, screened women had a
ignificant reduction of BC with axillary nodal involvement
0/5 versus 7/13, p < 0.01), suggesting a more favourable
ong-term prognosis [47]. Similarly, in an experience from
oronto, 6 out of 7 clinically detected BC had axillary nodal
nvolvement, whereas 4 out of 5 screen-detected BC were
CIS [45]. In all cases, it is important to give clear informa-
ion to women and physicians on the long-term breast cancer
isk, in order to perform a regular screening and facilitate
iagnosis of in situ or very small invasive cancers, with a
avourable long-term prognosis [48,49]. Finally, we can hope
hat optimal combinations of CT and involved field RT will
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educe the absolute risk of secondary BC in young patients
26,31,50,51].
. Conclusion
Breast cancer remains the most frequent second solid can-
er in teenagers and young women (10–30 years) treated for
odgkin’s disease. Median delay varies from 15 to 18 years
Table 4) [10,18,22,33,34,52,53]. The aetiology of these sec-
ndary breast cancers was complex, with several patients and
reatment-related intricate factors [54].
The rate of bilaterality was approximately 15% [55]. The
reat majority of the tumours (85–90%) were infiltrating
uctal carcinomas, with a 30% average of axillary nodal
nvolvement.
Breast-conserving treatment including whole breast irra-
iation is feasible for small tumours. An accurate radiological
nd clinical follow-up is mandatory in these patients in order
o find these secondary BC at the earliest stage [56,57].
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